- In a report published Tuesday, Evercore ISI analyst Mark Schoenebaum enumerated the upcoming catalysts for Biogen Idec Inc BIIB. These include:
Quarterly calls: Tecfidera sales number
March 2015 - ADPD Conference: BIIB-037 Ph 1b mild / prodromal alzheimer's detailed data
April 2015 (AAN Conference): Detailed LINGO (Optic Neuritis) Phase 2 data
1H15: Alprolix Kids B-Long Phase 3 data readout
2H15: Tysabri Phase 3 SPMS readout
2H15: Neublastin - Ph 2 Painful Lumbar Radiculopathy readout
2015: Tysabri Phase 2 acute ischemic stroke data
2015: Gazyva DLBCL Phase 3 data
2015: STX-100 - Ph2a IPF (n=32)
2016: Anti-LINGO - Ph 2 MS trial (SYNERGY)
Although interim results would be declared in 2H15, they could remain blinded, not offering any data, the analyst added.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.